Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration…
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals Professional…
Lucid Diligence Brief: Teva to acquire Emalex Biosciences
Lucid Diligence Brief: Teva to acquire Emalex Biosciences Professional…
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor…
Lucid Diligence Brief: Sun Pharma acquisition of Organon
Lucid Diligence Brief: Sun Pharma acquisition of Organon Professional audiences…
Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership
Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership Professional…
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional…
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……
Lucid Diligence Brief: MSD to acquire Terns
Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…
Lucid Diligence Brief: Dizal announces Zegfrovy (sunvozertinib) positive results in EGFR Exon20ins NSCLC
Lucid Diligence Brief: Dizal announces Zegfrovy (sunvozertinib) positive…